The promise: hundreds of tests, from a single drop of blood
Elizabeth Holmes dropped out of Stanford in 2003, at age 19, to found Theranos with an ambitious idea: developing a device, internally named 'Edison,' capable of running hundreds of different clinical tests from a single drop of blood obtained via a finger prick, instead of traditional venous blood draws. The promise combined two very appealing ideas: making clinical tests less invasive and, potentially, much cheaper and more accessible.
Holmes deliberately cultivated a public image evoking Steve Jobs (black turtlenecks included), and her narrative of a young genius set on revolutionizing medicine proved extraordinarily effective at attracting capital and media interest from very early on.
A high-profile board with little medical experience
Theranos built a board of directors that included names like former secretaries of state Henry Kissinger and George Shultz, former defense secretary James Mattis, and several former US senators, figures of enormous institutional prestige who lent almost instant credibility with investors and the media.
The problem, obvious in hindsight, was that virtually none of these board members had relevant experience in medical diagnostics, laboratory technology, or healthcare regulation, exactly the technical area where the company's central, and later proven false, claim resided.
What was really happening behind the Edison machine
in practice, Theranos's Edison device was unable to reliably run the vast majority of the tests the company publicly advertised. To keep offering the service to real patients at Walgreens clinics, Theranos diluted the tiny blood samples obtained from finger pricks and secretly processed them with conventional analysis machines bought from third parties, exactly the same technology it claimed to have surpassed.
Diluting a blood sample to run it on equipment designed for larger volumes introduces significant measurement errors, which led Theranos to issue potentially inaccurate clinical results to real patients, with direct medical consequences for treatment decisions in some documented cases.
The investigation that exposed the fraud: John Carreyrou and the Wall Street Journal
Starting in October 2015, journalist John Carreyrou published a series of investigations in the Wall Street Journal based on testimony from former employees, revealing the real shortcomings of Theranos's technology and the culture of extreme secrecy the company used to hide those shortcomings even from its own investors and business partners.
Carreyrou would later tell the full story in his book 'Bad Blood' (2018), which became the definitive account of the case and documented how the company went as far as legally threatening former employees who tried to raise the alarm about the technology's problems, in an active effort to silence any internal warning sign.
The outcome: a criminal conviction for its founder
Theranos shut down for good in 2018. Elizabeth Holmes and her former partner and chief operating officer, Ramesh 'Sunny' Balwani, were charged with fraud. Holmes was found guilty in January 2022 on several counts of investor fraud and sentenced to more than 11 years in prison, beginning her sentence in 2023. Balwani received a similar sentence in a separate trial.
Why 'fake it till you make it' doesn't work in medicine
Silicon Valley's tech culture often celebrates 'fake it till you make it': projecting more confidence and progress than actually exists while the product is still being developed, a practice that in many tech sectors is relatively harmless. The Theranos case illustrates why that same culture becomes directly dangerous when applied to a regulated sector where mistakes have direct medical consequences for real people.
For any investor, the structural lesson is twofold: a prestigious board doesn't substitute for the specific technical expertise needed to verify an extraordinary claim, and extreme secrecy about how a product actually works (versus the usual transparency of scientific validation) is, in itself, a warning sign that deserved far more scrutiny than it received for years.
Apply This Knowledge to Your Real Finances
eXcenda combines net worth, expenses, simulations, and macro context into a single app so you can move from theory to action.
Frequently Asked Questions
The company is estimated to have raised more than $700 million over its history, reaching a valuation of $9 billion at its peak in 2014.
The Edison device couldn't reliably run the vast majority of the tests it advertised. The company secretly processed most samples with conventional third-party machines, diluting the finger-prick samples so they could be used on that equipment.
She was sentenced in 2022 to more than 11 years in prison on several counts of investor fraud, and began serving her sentence in 2023.
Journalist John Carreyrou, of the Wall Street Journal, published a series of investigations starting in 2015 based on testimony from former employees, later told in full in his book 'Bad Blood' (2018).
Because despite its enormous institutional prestige, virtually none of its members had relevant technical experience in medical diagnostics or laboratory technology, the specific area where the company's central fraudulent claim resided.